Newer therapies in advanced prostate cancer |
| |
Authors: | Hegeman Robert B Liu Glenn Wilding George McNeel Douglas G |
| |
Affiliation: | Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Clinical Science Center, Madison, WI 53792, USA. |
| |
Abstract: | Prostate cancer is a leading cause of morbidity and mortality among males. Androgen ablation as initial therapy for advanced prostate cancer provides high response rates but does not cure disease, as nearly all men with metastases will eventually progress to hormone-refractory prostate cancer (HRPC). Present chemotherapy regimens for HRPC can provide palliation and have recently demonstrated an increase in overall survival. Over the past 2 decades, these regimens represent clear advances in the treatment of metastatic prostate cancer but also demonstrate that newer therapies are needed. Studies are ongoing to provide viable alternatives among traditional cytotoxic therapies as well as among novel agents targeting specific molecular pathways. This article reviews some of the newer therapies being developed and evaluated, including the epothilone analogues, human epidermal growth factor receptor pathway inhibitors, angiogenesis inhibitors, and endothelin receptor antagonists. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|